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Abstract 22	  
 23	  
 Vaccination is the most adequate method to control infectious diseases that 24	  
threaten the aquaculture industry worldwide. Unfortunately, vaccines are usually not 25	  
able to confer protection on their own; especially those vaccines based on recombinant 26	  
antigens or inactivated pathogens. Therefore, the use of adjuvants or immunostimulants 27	  
is often necessary to increase the vaccine efficacy. Traditional adjuvants such as mineral 28	  
oils are routinely used in different commercial bacterial vaccines available for fish; 29	  
however, important side effects may occur with this type of adjuvants. A search for 30	  
alternative molecules or certain combinations of them as adjuvants is desirable in order 31	  
to increase animal welfare without reducing protection levels. Especially, combinations 32	  
that may target specific cell responses and thus a specific pathogen, with no or minor 33	  
side effects, should be explored. Despite this, the oil adjuvants currently used are quite 34	  
friendlier with respect to side effects compared with the oil adjuvants previously used. 35	  
The great lack of fish antiviral vaccines also evidences the importance of identifying 36	  
optimal combinations of a vaccination strategy with the use of a targeting adjuvant, 37	  
especially for the promising fish antiviral DNA vaccines. In this review, we summarise 38	  
previous studies performed with both traditional adjuvants as well as the most 39	  
promising new generation adjuvants such as ligands for Toll receptors or different 40	  
cytokines, focusing mostly on their protective efficacies, and also on what is known 41	  
concerning their effects on the fish immune system when delivered in vivo.  42	  
 43	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1. Introduction 73	  
 74	  
Disease prevention by vaccination is, on economic, environmental and ethical 75	  
grounds the most appropriate method for pathogen control currently available to the 76	  
aquaculture sector. Traditionally, vaccines comprise either live-attenuated, replicating 77	  
pathogens or non-replicating, inactivated pathogens or their subunits. In many countries, 78	  
live vaccines are not approved for use in aquaculture for safety reasons, while 79	  
inactivated vaccines based on either killed pathogens or isolated non-replicating 80	  
pathogen subunits, are in many cases, weakly immunogenic. Thus, adjuvants or 81	  
immunopotentiators, are highly required for the elicitation of immune responses that 82	  
may be 100% protective against certain pathogens. 83	  
During the past, fish vaccines were made by a trial-and-error approach 84	  
(conventional vaccine design) including pathogen identification, pathogen cultivation, 85	  
and vaccine formulation containing whole cell preparation and oils. Through this 86	  
strategy, vaccines based on whole inactivated extracellular bacterial pathogens were 87	  
quite efficient; resulting in important reductions in mortalities and antibiotic usage in 88	  
the aquaculture industry [1]. However, many of the economically disastrous diseases of 89	  
today are due to intracellular pathogens, and for this type of pathogens the production of 90	  
effective vaccines has not been an easy task. In this sense, the most promising future 91	  
vaccines that induce protection against viruses are DNA vaccines. Intramuscular 92	  
injection of a DNA plasmid encoding an immunogenic antigen has proved very 93	  
effective in fish, in comparison to the results obtained in other animal models such as 94	  
mammals [2]. Because the antigen is produced by the fish cells, it is exposed on the cell 95	  
surface both directly or processed in the context of both major histocompatibility 96	  
complex (MHC) class I and MHC class II, thus effectively triggering both humoral and 97	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cellular immune responses. Although DNA vaccines offer a number of advantages over 98	  
conventional vaccines, there are still many aspects that may be optimised with adjuvant 99	  
help such as alternative routes of immunisation that allow mass-vaccination. Therefore, 100	  
fish vaccine approaches must be subjected to rational vaccine design wherein a 101	  
combination of a tailored adjuvant system with the most appropriate antigen is used to 102	  
create vaccines that may provide a more effective immune response against a specific 103	  
pathogen with minimal side effects.  104	  
On the other hand, many aspects of fish immunology are still unknown and we 105	  
are far from close to understanding on which immune mechanisms the protection 106	  
against many of these pathogens resides [3]. Moreover, as we know of today, there are 107	  
close to 22000 different fish species, and most of them have their “immune 108	  
peculiarities”. Without a doubt the innate defence system of fish is strongly developed 109	  
and may cope with many infectious agents, helping the fish to eradicate viruses, bacteria 110	  
and even parasites. However, many infectious agents resist innate defence mechanisms, 111	  
and then an adaptive immune response, present for the first time in evolution in teleost 112	  
fish, must come into play to fight these pathogens, being this adaptive response the 113	  
basis for vaccinology. The adaptive immune response provides the vertebrate immune 114	  
system with the ability to recognise and remember specific pathogens, to be able to 115	  
mount stronger and faster responses each time this pathogen is encountered. In higher 116	  
vertebrates, adaptive immunity to extracellular pathogens is generally mediated by 117	  
humoral immune responses (antibodies), while immunity to intracellular pathogens 118	  
(including viruses) often relies on cellular immune responses (cytotoxic T cells). In fish, 119	  
and despite the fact that the main elements for an adaptive immune response are present 120	  
in most species, the regulation of these elements greatly differs from mammalian 121	  
systems and even among different species. Both immunoglobulin (Ig) or B cell receptor 122	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(BCR) and T cell receptor (TCR) genes are known among all lineages of gnathostomes 123	  
(jawed vertebrates), but fish Ig are expressed as only as three isotypes (IgM, IgD and 124	  
IgT) with no isotype switching and low affinity maturation [4]. Interestingly, there is a 125	  
tight link between the innate and adaptive system that has not been much explored in 126	  
fish immunology. This link, governed by several innate receptors and signalling 127	  
molecules such as cytokines and transcription factors, may provide the key for the 128	  
future rational design of vaccine adjuvants, since recent advances in immunology have 129	  
shown that the magnitude and specificity of the signals perceived by the innate immune 130	  
cells following vaccination shape subsequent adaptive immune responses	  [5]. 131	  
 132	  
2. Principles of adjuvant actions 133	  
 134	  
Adjuvants (from Latin adjuvare meaning “to help”) have traditionally been 135	  
defined as helper substances that increase the magnitude of an adaptive response to a 136	  
vaccine (potency), or ability to prevent infection and death (efficacy). But nowadays 137	  
scientists have acknowledged that adjuvants may become more important in the way 138	  
adjuvants guide the type of adaptive response against a specific pathogen. Therefore, 139	  
adjuvants have been now defined as a group of structurally heterogeneous compounds 140	  
able to modulate the intrinsic immunogenicity of an antigen [6]. They can be classed 141	  
according to their chemical nature or physical properties, however since even related 142	  
compounds can have very different immunomodulating capacities, novel classifications 143	  
have focused on the immunological events they induce, even though for many of them 144	  
the exact mechanism of action is unknown. At present, the classification of adjuvants 145	  
that distinguishes between signal 1 facilitators and signal 2 facilitators has been widely 146	  
accepted [7]. According to this two-signal model, both the presentation of an antigen 147	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(signal 1) and the additional secondary signals (signal 2) are required for activation of 148	  
specific T and B lymphocytes, which form the adaptive arm of the immune system [8]. 149	  
The signal 1 facilitators influence the fate of the vaccine antigen in time, place, and 150	  
concentration, ultimately improving its immune-availability, while signal 2 facilitators 151	  
provide the co-stimulation signals during antigen recognition that will provide an 152	  
adequate environment for the most adequate antigen-specific immune response. 153	  
Another important aspect of the immune response against many adjuvants is the 154	  
recognition of microbes through the detection of conserved molecular patterns, 155	  
designated as pathogen-associated microbial patterns (PAMPs), through pathogen 156	  
recognition receptors (PRRs) that include Toll-like receptors (TLRs), NOD-like 157	  
receptors, dectin-1 or RIG-like helicases which are predominantly found on cells of the 158	  
innate immune system. Nowadays, this recognition is considered critical in signal 2 159	  
induction and downstream activation of distinct T helper cell subsets; however, other 160	  
authors make a distinction and refer to adjuvants that trigger PRRs as signal 0 161	  
adjuvants. In fact, recent work on adjuvants has especially focused on different PRR 162	  
ligands including different PAMPs, and as well as other endogenous TLR ligands 163	  
(Damage-associated molecular pattern molecules or	   DAMPs) such as heat-shock 164	  
proteins (hsp), studying their ability to induce targeted Th responses. Once there is a 165	  
production and expression of IL-2 (T cell growth factor) and its alpha-subunit of the IL-166	  
2 receptors (CD25) during e.g. activation of naïve Th cells into Th0 cells, proliferation 167	  
of Th cells starts. Th0 cells will differentiate to Th1 or Th2 cells depending on the 168	  
cytokine environment, wherein IFN-γ drives Th1 cells while IL-4 induces Th2 cell 169	  
production/differentiation [9]. Additionally, after many cell generations, the Th cells 170	  
progenitors differentiate to effector Th cells, memory Th cells and regulatory Th cells. 171	  
Different vaccine adjuvants that are in use in veterinary and human medicine aid 172	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differentiation of Th cells into several T cell lineages – such as Th1, Th2, Th9 and Th17 173	  
[10, 11]. In Table 1, we describe known adjuvant actions by both commercial and 174	  
experimental adjuvants, used mainly in human medicine. 175	  
 176	  
3. Signal 1 adjuvants used in fish vaccinology 177	  
 178	  
3.1. Oil emulsions 179	  
To increase the immunogenicity of an antigen, a slow release is often achieved 180	  
through the introduction of the antigen in the context of an emulsion. An emulsion is 181	  
defined as a dispersion of a liquid, called the dispersed phase, in a second liquid, called 182	  
the continuous phase in which the first one is not miscible. In vaccine formulations, 183	  
these phases are water (antigenic media) and oil. In order to stabilise the emulsions, 184	  
surfactants are added. A surfactant is a compound containing a polar group that is 185	  
hydrophilic and a non-polar group that is hydrophobic and often composed of a fatty 186	  
chain. Surfactants can be defined by their hydrophilic: lipohilic balance (HLB) value 187	  
that gives information on their relative affinity for both phases. According to the HLB 188	  
value of the surfactant, different kind of emulsions can be achieved [12]. Those having a 189	  
low HLB value have a high affinity for oily phases and render W/O emulsions, whereas 190	  
those with a high HLB value have a high affinity for the aqueous phase and render O/W 191	  
emulsions, which are well tolerated but induce a shorter term immune response. With 192	  
certain specific surfactant systems, when the HLB value is intermediate, W/O/W 193	  
emulsions can be achieved. In this case, the continuous phase is aqueous and the 194	  
dispersed phase is oil. But inside the oil droplets, an entrapped aqueous phase is found. 195	  
This type of emulsions has shown to generate long-term immune responses with various 196	  
antigens. 197	  
	   9	  
 198	  
3.1.1. Freund´s complete adjuvant 199	  
The most widely used and most effective adjuvant for experimental purposes has 200	  
been Freund´s complete adjuvant (FCA). FCA is composed of heat-killed Mycobacteria 201	  
and a mineral oil with surfactant [13]. Before injection, the antigen in an aqueous 202	  
solution is mixed with the FCA producing a stable W/O emulsion. Immunisation with 203	  
FCA and antigens results in strong Th1 and Th17 responses predominantly via the 204	  
MyD88 pathway. Unfortunately, the use of FCA has been associated with a variety of 205	  
severe side effects including injection site granuloma; therefore, the use of FCA has 206	  
been limited to research on animals including fish for establishing an effective immune 207	  
response. Furthermore, the use of FCA in fish has not always resulted in an increase in 208	  
immunogenicity or protection.  209	  
Pasteurellosis, caused by Pasteurella piscicida, also named Photobacterium 210	  
damsela subsp. piscicida is one of the major diseases in many species of wild and 211	  
farmed fish in Asia, USA and Europe. In yellowtail (Seriola quinqueradiata), a 212	  
susceptible species, vaccination against pasteurellosis has been assayed with a 213	  
lipopolysaccharide (LPS)-mixed chloroform-killed bacterin which resulted in protection 214	  
against challenge with the virulent bacterium. In this case, the inclusion of FCA in the 215	  
vaccine did not significantly enhance the protective effect [14]. 216	  
Streptococcus iniae is a Gram positive bacterium associated with disease in 217	  
several commercial species including tilapia (Oreochromis aureus and O. niloticus), 218	  
yellowtail, hybrid striped bass (Morone saxatilis), turbot (Scophthalmus maximus), and 219	  
rainbow trout (Oncorhynchus mykiss). Vaccination of rainbow trout with a formalin-220	  
killed culture of S. iniae resulted in good protection against experimental challenge that 221	  
was not significantly potentiated in the presence of FCA [15]. 222	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Aeromonas hydrophila is a Gram-negative bacterium known to cause motile 223	  
aeromonas septicemia (MAS) in freshwater fish farming. The major adhesin of A. 224	  
hydrophila, a 43 kDa outer membrane protein, was cloned, expressed and emulsified in 225	  
FCA to be used in a vaccine for the blue gourami (Trichogaster trichopterus) [16]. The 226	  
vaccine was intraperitoneally (i.p.) injected and after three weeks a booster was given 227	  
without FCA. Two weeks after the booster, the fish were challenged with two strains of 228	  
A. hydrophila. The recombinant adhesin protected against challenge with both the 229	  
homologous strain of A. hydrophila, and the heterologous strain, providing the same 230	  
immune protection as the native adhesin [16].  231	  
Aeromonas salmonicida is the etiological agent for furunculosis. In a study in 232	  
coho salmon (Oncorhynchus kisutch), formalin-killed A. salmonicida was i.p. injected 233	  
in the absence or presence of FCA. In this model, the best protection was found for the 234	  
FCA adjuvanted vaccine. Interestingly, fish injected with FCA (without antigen) gave 235	  
some protection even 90 days after challenge [17]. Injection of inactivated M. bovis may 236	  
induce innate defence mechanisms that may result a certain degree of protection to a 237	  
heterologous pathogen, as shown by Kato et al. [18] where Japanese flounder 238	  
(Paralichthys olivaceus) were partially protected against nocardiosis with FCA. In a 239	  
recent study, Zheng et al. [19] compared naturally occurring adjuvants (astragalus 240	  
polysaccharide and propolis) with FCA used in pentavalent vaccines. In that study, FCA 241	  
outcompeted the other adjuvants although the natural adjuvants induced some 242	  
immunostimulant activities. 243	  
It has generally been difficult to develop effective vaccines against A. 244	  
hydrophila most probably because of the high degree of antigenic variation [17, 21, 22], 245	  
this is in contrast to vaccines against Gram-negative pathogens of salmonids like 246	  
Aliivibrio salmonicida, Vibrio anguillarum, Yersinia ruckerii and A. salmonicida – 247	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where vaccines show up to 100% efficiency. Recently, a vaccine against A. hydrophila 248	  
giving protection in rainbow trout was prepared [20]. LaPatra and co-workers developed 249	  
a new challenge model in rainbow trout with A. hydrophila by injection into the dorsal 250	  
sinus to determine the efficacy of a bacterial lysate. The vaccine was shown to give 251	  
protection after i.p administration, and this protection could be potentiated in the 252	  
presence of FCA [20]. Also, fish that survived an A. hydrophila challenge were very 253	  
resistant to re-infection.  254	  
Flavobacterium psychrophilum is a widespread Gram-negative pathogen in 255	  
freshwater causing rainbow trout fry syndrome (RTFS) and bacterial cold water disease 256	  
(BCWD) [23]. In addition to rainbow trout, coho salmon is the most susceptible species 257	  
together with other non-salmonid species that are also affected. Injection of a low 258	  
molecular weight fraction emulsified in FCA resulted in an enhanced level of protection 259	  
for rainbow trout [23]. 260	  
Flavobacterium columnare is a Gram-negative bacterium responsible for 261	  
columnaris disease. The disease was first described in 1917 in several warm water fish 262	  
species from the Mississippi river, and since has been isolated from freshwater fish 263	  
species worldwide [24]. Specific antibodies were found in tilapia plasma and mucus 264	  
following i.p. injection of formalin-killed sonicated or whole cells of F. columnare in 265	  
FCA within 2 weeks. After a secondary immunisation, the antibody response increased 266	  
and at 10 weeks post-immunisation the titre remained elevated. Also, antibodies were 267	  
observed in cutaneous mucus in fish i.p. immunised with formalin-killed sonicated cells 268	  
(ultrasound disrupted cells) in FCA 6 and 8 weeks post-immunisation	  [24].  269	  
 270	  
3.1.2. Freund´s incomplete adjuvant 271	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Because of its high toxicity, the use of FCA has been widely replaced by 272	  
Freund´s incomplete adjuvant (FIA) that lacks the mycobacterial components of the 273	  
emulsion, being therefore just a W/O emulsion. This adjuvant is still highly effective in 274	  
vaccination with a significant reduction of toxicity, however, some important side 275	  
effects are still present, effects very well detailed for Atlantic cod (Gadus morhua) in a 276	  
very recent paper [25].  277	  
Edwardsiella tarda is a Gram negative intracellular bacterium that can infect 278	  
both marine and freshwater fish, including Japanese flounder. In order to develop 279	  
effective vaccines against this pathogen, fish were i.p. injected with a vaccine 280	  
containing a major antigenic protein of E. tarda in the absence or presence of FIA [26]. 281	  
Protection against experimental challenge achieved by the vaccine without adjuvant 282	  
resulted in a relative per cent survival (RPS) of 34% that was increased to 81% in the 283	  
presence of FIA. Moreover, vaccination with the oil-adjuvanted antigen stimulated the 284	  
expression of a series of genes like complement component 3 (C3), MHC class I and 285	  
MHC class II, CD8α, CD40, Mx, interferon γ (IFN-γ), tumour necrosis factor α (TNF-286	  
α) and interleukin 6 (IL-6), whereas vaccination with the antigen alone resulted in 287	  
increased expression of just IgM, MHC class I and class II, and Mx [26]. 288	  
Nocardia seriolae is a Gram-positive acid-fast bacterium that causes nocardiosis 289	  
in cultured marine and freshwater fish in Taiwan, Japan and China. Although the 290	  
disease results in considerable economic loss, no commercial vaccines are available. 291	  
Very recently, an oil-adjuvanted vaccine was developed and tested on protection against 292	  
challenge with a virulent strain [27]. Formalin-inactivated whole cell antigen was used 293	  
as a vaccine with or without FIA, however, and even though antibody levels increased, 294	  
no protective effects were found.    295	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Another Gram-positive bacterium that causes disease (lactococcosis) and 296	  
mortality in rainbow trout is Lactococcus garvieae. Recently a vaccine was prepared 297	  
based on formalin inactivated bacterin or bacterin together with FIA. Fish were given 298	  
i.p. injections and challenged by exposure to virulent bacteria 30, 75, and 125 days after 299	  
vaccination [28]. A hundred and twenty five days after vaccination the RPS in fish 300	  
vaccinated with bacterin only was 54% and whereas it was 85% in fish vaccinated with 301	  
bacterin together with FIA. 302	  
Tenacibaculum maritimum is a marine bacterium that causes flexibacteriosis 303	  
worldwide. In Australia (Tasmania), Atlantic salmon (Salmo salar) and rainbow trout 304	  
are the most heavily affected species, and due to the lack of vaccines, so far the disease 305	  
has been treated with trimethoprim and oxytetracycline with the subsequent negative 306	  
impact on the environment [29]. Salmon injected with formalin inactivated bacteria 307	  
mixed with FIA provided protection against challenge with T. maritimum while the 308	  
vaccine without the adjuvant could not provide sufficient protection against a moderate 309	  
challenge of T. maritimum. 310	  
Infection with fungi oomycetes such as Aphanomyces invadans may cause heavy 311	  
mortalities of fresh water and estuarine fish species as a result of granulomatous 312	  
inflammation. In catla (Catla catla Hamilton), fungal extract combined with FIA 313	  
showed to increase both the survival rate during experimental challenge with A. 314	  
invadans and the antibody response compared to non-adjuvanted vaccines	  [30]. 315	  
 316	  
3.1.3. Montanide  317	  
Mineral oil adjuvants registered under the trademark of Montanide have been 318	  
optimised in order to improve efficacy and stability of vaccine formulations and to 319	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reduce side effects. These adjuvants are based on either mineral oil, non-mineral oil or a 320	  
mixture of both, as well as those made from specific surfactant chemistry using 321	  
mannitol oleate and may be used to manufacture different type of emulsions, W/O, O/W 322	  
or W/O/W, for use in both mammals and fish [31, 32]. 323	  
Philasterides dicentrarchi is a scuticocilate parasite that causes mortalities and 324	  
significant economic losses in cultured turbot [33]. An important attempt to optimise a 325	  
vaccine against this parasite was performed on the basis of antigenic dose, concentration 326	  
of inactivating agent (formalin) and proportion of the adjuvant Montanide ISA763A 327	  
(W/O, non-mineral oil) in the emulsion. The results of the study showed that a high 328	  
concentration of antigen, 0.2 % formalin and 50 % adjuvant generated the longest time 329	  
of survival after challenge 30 days after the second injection, and the highest levels of 330	  
antibodies in the vaccinated fish [33]. 331	  
Pseudomonas plecoglossicida is a bacterium causing bacterial hemorrhagic 332	  
ascites of cultured ayu (Plecoglossus altivelis). To develop a vaccine against the 333	  
disease, formalin-killed P. plecoglossicida bacterin was emulsified with Montanide and 334	  
injected i.p. The fish were challenged with an i.p injection of virulent P. plecoglossicida 335	  
22 and 52 days after vaccination [34]. The RPS of vaccinated fish was 17-58% without 336	  
adjuvant, 57-92% with Montanide ISA711 and 65-86% with Montanide ISA763A. 337	  
Another study on the same disease and adjuvant (Montanide ISA 763A) concluded that 338	  
there is a good correlation between antibody levels and protection against disease in a 339	  
challenge test [35]. 340	  
To study the efficacy of different adjuvants in Atlantic halibut (Hippoglossus 341	  
hippoglossus), fish were injected i.p. with a model vaccine of human gamma globulin 342	  
with either FCA or Montanide ISA711 as adjuvants [36]. Antibody responses and 343	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intraperitoneal adhesions were examined every month for up to 12 months. FCA 344	  
produced the highest and fastest antibody response, since in the group injected with the 345	  
Montanide adjuvant only 4 of 47 fish reached a titre of 1:1000 (month 6) compared to 346	  
27 of 48 fish in the FCA group (after 2 months), however, FCA also induced the fastest 347	  
intraperitoneal adhesions [36]. 348	  
In a very recent study in carp (Cyprinus carpio), a recombinant S-layer protein 349	  
of A. hydrophila was used to assess the ability to protect fish against six virulent isolates 350	  
of A. hydrophila. The recombinant S-layer protein of A. hydrophila was produced, 351	  
diluted in phosphate buffered saline and mixed with a Montanide adjuvant at a ratio of 352	  
30:70. Common carp were i.p. injected with the emulsion, and after 35 days the fish 353	  
were challenged with six different isolates of A. hydrophila [37]. The RPS values varied 354	  
between the different challenge isolates (40-75%), but they suggested that the S-layer 355	  
protein together with Montanide adjuvant is a good candidate for an efficacious vaccine. 356	  
Furthermore, Montanide ISA-763 has also been used as an adjuvant in 357	  
experimental bivalent vaccine for L. garvieae and A. hydrophila with high degree of 358	  
efficacy in rainbow trout [38]. 359	  
 360	  
3.1.4. Other mineral oil adjuvants 361	  
Moritella viscosa is the causative agent of winter ulcers in farmed fish like 362	  
Atlantic salmon and Atlantic cod. Vaccination of Atlantic salmon against M. viscosa is 363	  
performed with oil-adjuvanted polyvalent injection vaccines based on formalin-364	  
inactivated bacterial cultures, using an AJ-oil (Alpha Ject 5200) used in some vaccines 365	  
commercialised by Pharmaq [39]. However, a multivalent commercial salmon vaccine 366	  
containing M. viscosa as one of five bacteria mixed in a mineral oil adjuvant (Alpha Ject 367	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5200) did not protect turbot against challenge [40], whereas moderate intra-abdominal 368	  
adhesions were detected in vaccinated fish.  369	  
Other commercial oil-adjuvanted vaccines have been shown to give protection in 370	  
Atlantic salmon against bacterial diseases like vibriosis, coldwater vibriosis and 371	  
furunculosis for a long time. However, side effects and retardation in growth have been 372	  
clearly demonstrated [41, 42]. Mutoloki and co-workers investigated the intraperitoneal 373	  
lesions induced by an oil-adjuvanted vaccine against infection with A. salmonicida and 374	  
M. viscosa in Atlantic salmon	  [43]. The cellular composition was typical of granulomas 375	  
containing large macrophages, eosinophilic granular cells, lymphocytes and 376	  
multinucleated cells.  377	  
Oil-adjuvanted vaccines are also used to control sea bass (Dicentrarchus labrax) 378	  
against bacterial diseases like vibriosis and pasteurellosis. Sea bass is one of the most 379	  
explored fish species in the Mediterranean area, and suffers from infection by V. 380	  
anguillarum and Photobacterium damsela subsp. piscicida. Oil-adjuvanted vaccines 381	  
against these diseases have been prepared and injected i.p., but despite their 382	  
effectiveness, granulomatous peritonitis was also recognised [44]. 383	  
The major bacterial disease of farmed Atlantic cod is classical vibriosis [45]. 384	  
Cod vaccinated by injection with mineral oil adjuvanted vaccines against both V. 385	  
anguillarum and atypical A. salmonicida were very well protected against homologous 386	  
challenges [46]. In this model, even without adjuvant the fish were protected against V. 387	  
anguillarum, but not against atypical A. salmonicida challenge.    388	  
 389	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3.2. Nano/ microparticles as adjuvants 390	  
Microparticles offer a promising option to oil emulsions, and their beneficial 391	  
use as carriers for vaccine delivery has been widely discussed [47]. An association 392	  
or/and encapsulation of antigen(s) with/in microparticles can be achieved by covalent 393	  
linkage or physical entrapment. Compared to the latter technique, where the antigen is 394	  
non-covalently and physically incorporated in the interior of the microparticle, covalent 395	  
coupling offers distinct advantages: fewer amount of antigen is required; processing and 396	  
presentation by antigen-presenting cells is more efficient; a higher stability during 397	  
storage is obtained and any excess of (valuable) material can easily be regained. With 398	  
the use of microparticles, a very low dose of antigen can give rise to an optimal humoral 399	  
response. 400	  
The structure and the properties of microparticles may change markedly with 401	  
slight alterations in production conditions, but nanoparticles can be prepared in a 402	  
physico-chemically reproducible manner within narrow size limits. For this reason, 403	  
adjuvants on the basis of these submicron polymeric particles were developed and have 404	  
also been suggested for use as potent adjuvants in mammalian systems [48].  405	  
 406	  
3.2.1. PLGA particles 407	  
Encapsulation of vaccines in biocompatible and biodegradable Poly-(lactide-co-408	  
glycolide) (PLGA) polymers has been studied for over twenty years. Antigen is released 409	  
from the microspheres by diffusion through matrix pores and by matrix degradation. 410	  
Biodegradation rates can be regulated by alterations in polymer composition and 411	  
	   18	  
molecular weights. In addition, there is often instant release of surface associated 412	  
antigens that may be beneficial to aid a rapid response. 413	  
So far, a few studies have been carried out on fish with regard to uptake and 414	  
degradation of PLGA particles and the immune response obtained. For the most part, 415	  
these studies have been on oral administration [49-53]. A recent article appeared on 416	  
parenteral immunisation of Indian major carp, rohu (Labeo rohita) with PLGA 417	  
encapsulated antigen	   [54]. Outer membrane proteins (OMP) of A. hydrophila were 418	  
encapsulated in PLGA microparticles and mixed with FIA in an emulsion or 419	  
administered alone by i.p. injection in rohu. Twenty-one and 42 days after 420	  
immunisation, the antibody titres were significantly higher in the PLGA-encapsulated 421	  
antigen group containing FIA [54].  422	  
A dose-dependent transient increase of antibody response following i.p injection 423	  
of PLGA particles containing human gamma globulin (HGG) has been shown by 424	  
Fredriksen and Grip [55] where it was shown that microparticle carriers were superior 425	  
compared to nanoparticles. Furthermore, when the formulation of PLGA entrapped 426	  
HGG was performed with ß-glucan or oil, it resulted in a continuous increase of 427	  
antibodies over time (over 120 days). 428	  
Oral vaccines encapsulated in PLGA have been also used in Japanese flounder 429	  
[51, 53] and salmonids like rainbow trout [50, 52, 56] or Atlantic salmon [49]. In the 430	  
case of Japanese flounder, a plasmid encoding the major capsid protein of lymphocystis 431	  
disease virus (LCDV) was constructed and encapsulated in PLGA. Controls were naked 432	  
plasmid vaccine and blank PLGA particles	  [53]. The fish were orally intubated, and 28 433	  
days post vaccination the fish were challenged by intramuscular injection with LCDV. 434	  
Vaccine-effects were evaluated by observing the presence of lymphocystis nodules. The 435	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cumulative percentage of Japanese flounder with nodules after challenge was greatly 436	  
reduced in the group receiving the plasmid coding for the LCDV protein in PLGA 437	  
particles in the period of 15 to 120 days post-immunisation [53]. In addition, the levels 438	  
of antibody in sera of fish vaccinated with PLGA microcapsules increased for up to nine 439	  
weeks; although from this point it started to decrease [51].  440	  
In rainbow trout, oral vaccination (as a feed additive) against lactococcosis was 441	  
attempted with antigens encapsulated in PLGA particles [52]. RPS of the PLGA-442	  
vaccine amounted to 63 % and booster vaccination with oral administration of the 443	  
PLGA-vaccine gave a RPS of more than 60 % 120 days after the first vaccination. Also 444	  
in rainbow trout, human gamma globulin (HGG) was microencapsulated in PLGA [50]. 445	  
Specific antibodies were detected in the intestinal mucus of fish that were administered 446	  
with the microencapsulated antigen after boosting with soluble HGG, but not in fish that 447	  
were primed with the soluble antigen. The fate of orally administered HGG in Atlantic 448	  
salmon was determined, demonstrating that fifteen minutes after administration, the 449	  
HGG-PLGA was found in the intestine resembling the observation for free HGG [49]. 450	  
The results from this study indicate that orally delivered HGG-PLGA had higher levels 451	  
and greater persistence of HGG systemically than free HGG.  452	  
Finally, feeding of rainbow trout with feed containing plasmid DNA encoding 453	  
IHNV G protein induced slightly higher amount of neutralising antibodies against 454	  
IHNV but no increased survival after experimental challenge with IHNV [56]. 455	  
 456	  
3.2.2. ISCOMs	  457	  
Immune-stimulating complexes (ISCOMs) were conceived to co-formulate antigen 458	  
and adjuvant in a particle [57]. ISCOMs represent an interesting approach to stimulation 459	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of the humoral and cell-mediated immune response towards amphipathic antigens. They 460	  
are relatively stable but non-covalently-bound complex of approximately 40 nm 461	  
diameter of saponin adjuvant Quil-A (saponin extracted from the cortex of the South 462	  
American tree Quillaja saponaria molina), cholesterol and amphipathic antigen in a 463	  
molar ratio of approximately 1:1:1. ISCOMs produced through the patented MatrixTM 464	  
technology by Isconova have been widely studied in combination with different 465	  
veterinary vaccines, and are currently incorporated in a number of commercialized 466	  
animal vaccines. At this moment, Pharmaq is studying the introduction of these 467	  
adjuvants in commercialised fish vaccines.  468	  
 469	  
 470	  
4. Signal 2 facilitators and TLR ligands as adjuvants or immunostimulants 471	  
 472	  
A large number of adjuvants that have been investigated do not directly affect 473	  
the concentration and distribution of antigen between injection site and presentation site 474	  
(this has not been established in fish yet). This category of vaccine adjuvant has 475	  
dominated the literature on vaccine research in the last decade, and comprises the 476	  
category of signal 2 facilitators, which include stranger and danger molecules, as well as 477	  
inflammatory cytokines. 478	  
A number of so-called toll-like receptors (TLR) ligands (agonists) may induce 479	  
strong innate responses that may be decisive for the outcome of acquired responses. 480	  
Teleost fish species may possess close to twice the number of different TLR compared 481	  
to mammalian species presumably due to an ancient genome duplication event. Many 482	  
similarities between mammalian and fish with respect to intracellular and downstream 483	  
signaling events exist, but there are dissimilarities that warrant focus. In this issue, a 484	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detailed review authored by Aoki and Robertsen has been included, giving an excellent 485	  
overview of the current knowledge on fish TLR (technical editor: Check whether this 486	  
review is included in the special issue, and give reference). Another up-to-date review 487	  
on immune relevant genes including TLR-like receptors in fish is also authored by Zhu 488	  
et al. [58]. In general, those TLRs that, after ligand binding, induce the production of 489	  
IL-12 favour a Th1 response (TLR 3, 4, 5, 7, 8, 9 and 11) and in addition, the activation 490	  
of these TLRs may induce cross-presentation of antigens facilitating a cytotoxic T cell 491	  
response under certain conditions [59]. It should be mentioned that ligand binding to 492	  
TLRs 3 and 4, 7 and 9 may also induce type I IFN responses via interferon regulating 493	  
factors. Within this group of signal 2 facilitators, we have also included alum, as it has 494	  
been recently discovered that this adjuvant directly interacts with dendritic cells in a 495	  
similar way to that of danger signals [60]. 496	  
 497	  
4.1. Aluminium containing adjuvants 498	  
The adjuvant property of aluminium salts was discovered in 1926	   [61]. 499	  
Aluminium compounds, especially aluminium phosphate and aluminium hydroxide, are 500	  
some of the few adjuvants that have been allowed and considered safe to use in human 501	  
vaccines. Aluminium adjuvants have been shown to induce Th2 responses almost 502	  
exclusively [26], thus they have been used as adjuvants with great success, being 503	  
particularly effective at promoting protective humoral immunity. However, alum is not 504	  
optimally effective for diseases where cell-mediated immunity is required for 505	  
protection. It was believed that alum activates NLRP3 inflammasome and induces 506	  
necrotic cell deaths that release the danger signal uric acid [62]. However, very recently, 507	  
it has been discovered that being a crystal, alum binds dendritic cell plasma membrane 508	  
lipids with substantial force, independent of inflammasome and membrane proteins 509	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[60]. The subsequent lipid sorting activates an abortive phagocytic response that leads 510	  
to antigen uptake. Such activated dendritic cells, without further association with alum, 511	  
show high affinity and stable binding with CD4+ T cells via the adhesion molecules 512	  
intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated 513	  
antigen-1 (LFA-1). Only a few studies have been performed with aluminium adjuvants 514	  
in the optimization of fish vaccines.  515	  
Fifteen years ago a vaccine against A. salmonicida mixed with potassium 516	  
aluminium sulphate (alum) as an adjuvant was tested in Atlantic salmon [63]. Alum 517	  
appeared to enhance the protection against challenge, but not at a statistically significant 518	  
level. In another study, an Escherichia coli mutant was used for vaccination against 519	  
Edwardsiella ictaluri-induced enteric septicaemia of catfish (Ictalurus punctatus). 520	  
Killed E. coli bacteria with or without alum were administered i.p to catfish and the fish 521	  
were challenged with virulent E. ictaluri bacteria [64]. Fish given E. coli in alum 522	  
showed an enhanced survival (92 %) compared with the fish for which E. coli was 523	  
administered alone (54%) or fish given saline (56 %).  524	  
Recently, an aluminium hydroxide adjuvanted E. tarda vaccine was prepared 525	  
and injected i.p in Japanese flounder. The RPS was found to be 69 % [26] while 526	  
immunisation with the antigen alone followed by an experimental challenge gave a RPS 527	  
of 34, however, the FIA coupled vaccine showed a RPS of 81%.  528	  
Another experiment has been recently carried out by Fan et al. [65], in which 529	  
formalin-inactivated reddish body iridovirus (TRBIV) were mixed with alum and either 530	  
injected or bath administered twice in turbot. The resulting RPS calculated was 83.3% 531	  
and 90.5%, respectively. 532	  
 533	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4.2. ß-glucans – ligands for dectin-1 534	  
ß-glucans are known to stimulate the non-specific immune response of both 535	  
mammals and fish where dectin-1 may be involved [66, 67]. To obtain protective effects 536	  
against diseases the glucan is injected i.p., and there seems to be a dosage-dependent 537	  
and short-lived protection. In addition, there are some reports on the adjuvant effect of 538	  
ß-glucans [41, 42, 68-75]. 539	  
DeBaulney and co-workers prepared an oral vaccine against vibriosis for use in 540	  
turbot, and after feeding the vaccine for 5 days the fish were challenged 28 days 541	  
thereafter. Fish given the vaccine alone resulted in a RPS of 52 %, while a combination 542	  
of the vaccine and the ß-glucan gave a RPS on 61 %, higher protection levels but not 543	  
statistically different from the vaccine alone [71]. In 1998, an attempt to establish 544	  
immunisation protocols to obtain the highest immune response against V. damsela was 545	  
performed in Spain [72]. In this study they i.p. injected the O-antigen of V. damsela in 546	  
combination with ß-glucan. As a correlate to vaccine efficacy, the phagocytic index of 547	  
head kidney macrophages was evaluated. The obtained results were as follows: the 548	  
enhancement of the phagocytic index lasted longer in fish injected with ß-glucan at the 549	  
same time or after being injected with the antigen when compared with fish injected 550	  
with ß-glucan before the antigen. Similar results were obtained with regard to antibody 551	  
titres [72].    552	  
Yeast glucan (mainly a ß-1,3-D glucan) was included in a furunculosis vaccine 553	  
that consisted in a formalin-killed culture of A. salmonicida and V. salmonicida [70]. 554	  
The vaccine, either with or without ß-glucan, was injected i.p. and salmon challenged 3-555	  
46 weeks after vaccination. Vaccines supplemented with ß-glucan induced significantly 556	  
higher protection against furunculosis than vaccines without this adjuvant [70], but ß-557	  
glucan alone did not result in protection after 11 weeks. In another study, ß-glucan-558	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adjuvanted vaccines against furunculosis seemed to give protection at an early time-559	  
point after vaccination (6 weeks), but no protection was seen after 3 and 6 months [41]. 560	  
As a side effect, the average weight of the ß-glucan-adjuvanted group was significantly 561	  
lower compared to the controls, but the weight of fish given oil-adjuvant was also 562	  
significantly lower than the ß-glucan-adjuvanted group [42]. In a further study 563	  
performed in coho salmon, Nikl et al. evaluated the potentiating effect of seven 564	  
substances on the protection after vaccination with formalin-treated A. salmonicida 565	  
bacterin [68]. Statistically significant improvement in survival over the group receiving 566	  
bacterin alone was noted in fish groups that also received ß-glucans like Vitastim-Taito 567	  
and lentinan. However, agglutinin levels were significantly elevated in all cases where 568	  
the bacterin was injected, and no significant elevation in agglutinin titer occurred as a 569	  
result of combining an immunostimulant with the bacterin [68].  570	  
Catla is one of the major Indian carp species often affected with A. hydrophila, 571	  
thus a formalin-inactivated A. hydrophila vaccine was developed and protection was 572	  
studied in the absence and presence of a ß-glucan adjuvant [74]. A reduction in 573	  
mortality was found in the presence of ß-glucan compared to the vaccine itself, although 574	  
the differences were not statistically significant (RPS of 67.7 % and 58.0% with and 575	  
without the adjuvant, respectively). In carp, a vaccine against A. hydrophila showed a 576	  
higher antibody titer when ß-glucan was i.p. injected prior to vaccination, while bath 577	  
and oral administration of ß-glucan before vaccination did not result in enhanced 578	  
antibody response [75]. In a further study by Selvaraj and coworkers, carp were 579	  
vaccinated against A. hydrophila with LPS from a virulent strain of the bacterium in the 580	  
presence of different concentrations of ß-glucan and administered through various 581	  
routes such as i.p, oral or bath [76]. The RPS was significantly higher in i.p. injected 582	  
groups even at the lowest concentration of ß-glucan and fish given a mixture of LPS and 583	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ß-glucan orally obtained a higher RPS compared to controls. The administration of the 584	  
LPS-glucan by bath did not result in increased survival, and antibodies were never 585	  
detected in fish vaccinated either orally or by bath. However, no possible analysis of the 586	  
contribution of β-glucan in the vaccine efficacy could be established because an obvious 587	  
control group in this study was missing, namely the protective effect of LPS without 588	  
adjuvant [76]. 589	  
In another study, the i.p. injection of ß-glucan on days 1 and 3 followed by two 590	  
i.p. immunisations of E. ictaluri on days 7 and 14 performed in channel catfish resulted 591	  
in higher serum antibody levels relative to catfish receiving PBS instead of ß-glucan 592	  
before administration of E. ictaluri [69]. Serum antibody levels were determined on day 593	  
7 (day 21) after the last immunisation, reaching with ß-glucan antibody titers that were 594	  
typically two-fold higher than those of fish without ß-glucan. 595	  
In order to investigate possible treatments against A. hydrophila in blue gourami, 596	  
laminaran, a ß-1,3-D-glucan, was injected i.p. in the absence and presence of formalin-597	  
killed A. hydrophila bacteria [77]. A single i.p. injection of 20 mg kg-1 laminaran alone 598	  
was sufficient to protect the fish against infection by a virulent strain of A. hydrophila 599	  
up until 29 days after injection in correlation with an increased phagocytic activity of 600	  
head kidney phagocytes. Despite this, the addition of 20 mg kg-1 laminaran to a 601	  
formalin-killed A. hydrophila did not significantly improve the protection [77]. 602	  
 603	  
4.3. Saponins 604	  
Saponins are natural glycosides of steroid or triterpene which have been widely 605	  
explored as adjuvants in different mammalian systems due to their capacity to stimulate 606	  
both Th1 and Th2 responses [78]. The most widely used saponins are Quil A 607	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(component of ISCOMs) and their derivatives, however, due to their high cytotoxicity 608	  
and instability in aqueous phase, the use of different kinds of saponins is being 609	  
explored.   610	  
In Japanese flounder, formalin-killed E. tarda cells were administered to fish by 611	  
feeding in the absence or presence of curdlan or curdlan together with Quil A saponin. 612	  
Although the incorporation of curdlan gave higher survival rates, only the group in 613	  
which the vaccine was administered with both curdlan and Quil A showed significantly 614	  
better survival [73]. 615	  
 616	  
4.4. Poly I:C – toll-like receptor 3 agonist 617	  
Polyinosinic polycytidylic acid (poly I:C) is a double stranded 618	  
polyribonucleotide, that mimics a viral infection and therefore has been widely used to 619	  
induce a type I IFN in many species including fish [79-81].	  IFNs are cytokines with a 620	  
major role in the early defence against viral infections, thus Poly I:C induces a non-621	  
specific antiviral state after its binding to TLR3 and the subsequent activation of 622	  
intracellular signalling events. This non-specific antiviral activity of Poly I:C has been 623	  
recently tested in rainbow trout infected with infectious hematopoietic necrosis virus 624	  
(IHNV) [82]. Fish pre-injected with Poly I:C were protected against IHNV challenge 2 625	  
days later and IHNV-specific antibodies were detected in survivors. The survivors 626	  
showed a 100% survival rate following re-challenge with IHNV both 21 and 49 days 627	  
after the primary IHNV challenge [82], demonstrating that the fact that fish were at an 628	  
antiviral state during the encounter of a virus, gave them an important advantage for 629	  
posterior specific antibody production. A similar study was performed in the sevenband 630	  
grouper Epinephelus septemfasciatus in which fish were immunised against the 631	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nodavirus red-spotted grouper nervous necrosis virus (RGNNV) [83]. Fish injected with 632	  
50 mg Poly I:C fish-1 or more intramuscularly (i.m.) and challenged i.m. with RGNNV 633	  
2 days post-injection showed more than 90% survival rate. When surviving fish were re-634	  
challenged with RGNNV 3 weeks after the primary challenge, no mortalities were 635	  
detected in the group that had been previously exposed to Poly I:C, since upon RGNNV 636	  
challenge the antibodies against RGNNV were higher in these fish. All survivors that 637	  
were re-challenged with RGNNV showed even higher levels of specific antibodies. In 638	  
addition, the RGNNV titres in brain tissues of the survivors in the Poly I:C-RGNNV-639	  
RGNNV group were all under the detection limit [83]. Following up this work, this 640	  
research group conducted a field trial exploring the vaccine efficacy of a RGNNV 641	  
vaccine followed by Poly I:C injection. The Poly I:C-adjuvanted vaccine showed 642	  
reasonable efficacy, but a one-shot Poly I:C injection in sevenband grouper 20 days 643	  
after a natural RGNNV outbreak also induced a high survival rate (93.7%) compared to 644	  
non-treated fish (9.8%) [84]. 645	  
A prophylactic strategy using poly I:C was also used by Takami and co-workers 646	  
in Japanese flounder experimentally infected with viral haemorrhagic septicaemia virus 647	  
(VHSV) [85]. The survival rate in Japanese flounder after VHSV challenge following 648	  
Poly I:C administration was 100%, while all untreated fish died within 9 days. Survival 649	  
rates of the fish given a secondary challenge VHSV were 100% in the Poly I:C-VHSV 650	  
group (Poly I:C-VHSV-VHSV group), while non-immunized fish showed a 0% 651	  
survival. 652	  
 653	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4.5. Lipopeptides 654	  
Lipoproteins and lipopeptides have been found in a large number of 655	  
microorganisms, the most prominent being mycobacteria and mycoplasms. These 656	  
molecules have been found to exhibit both a strong innate (inflammatory) response and 657	  
a long-lasting adaptive immune response in mammals. Very few studies have been 658	  
performed on lipopeptides in fish. The adjuvant effect of polar glycopeptidolipids in 659	  
experimental vaccines against A. salmonicida was investigated [86]. Polar 660	  
glycopeptidolipids (pGPL-Mc) were extracted from Mycobacterium chelonae, which is 661	  
one of three mycobacteria species that are fish-pathogenic. At 12 weeks post 662	  
vaccination, the antibody response of fish given 0.25 mg kg-1 pGPL-Mc in combination 663	  
with an A. salmonicida bacterin was significantly higher than that induced by a non-664	  
adjuvanted bacterin. Increased doses of pGPL-Mc suppressed the antibody response, 665	  
while no significant side effects were observed in the peritoneal cavity after use of this 666	  
adjuvant [86].  667	  
 668	  
4.6. Flagellin – toll-like receptor 5 agonist 669	  
The structural protein of Gram-negative flagella is called flagellin. Flagellin is a 670	  
potent activator of a broad range of cell types within the innate and adaptive immune 671	  
system. Several studies have demonstrated the ability of flagellin as an adjuvant, 672	  
promoting cytokine production [87]. Flagellin is known to induce immune responses via 673	  
the TLR5 signalling resulting in a mixed Th1 and Th2 response, although it has also 674	  
been reported that inflammasomes containing NLRC4/IPAF may bind cytosolically 675	  
located flagellin [62]. During the last decade, the adjuvant effect of flagellin has widely 676	  
been studied in vertebrates and during the last couple of years also in fish [88-90] 677	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Piscirickettsiosis is a severe disease reported in salmonids that has caused 678	  
especially great problems for the Chilean aquaculture industry. In 1989, the bacterium 679	  
Piscirickettsia salmonis was isolated from a moribund coho salmon and was found to be 680	  
the etiological agent of this disease. The pathogen is a Gram-negative obligate 681	  
intracellular bacterium. The disease has also been reported to affect Atlantic salmon, 682	  
rainbow trout and other farmed salmonid species [88]. A recombinant subunit vaccine 683	  
was developed in order to control the disease due to poor responses after treatment by 684	  
antibiotics. Three experimental formulations were prepared containing two or three 685	  
recombinant proteins of the bacterium, and the formulations were emulsified with one 686	  
volume of FIA [88]. The highest protective response was obtained with a vaccine 687	  
formulation containing the subunit of the flagellum and chaperonins Hsp60 and Hsp70 688	  
of P. salmonis, suggesting that the use of more than one recombinant protein antigen is 689	  
needed to obtain a good protective effect against this disease. 690	  
Jiao and co-workers have been studying different vaccine concepts against E. 691	  
tarda in the Japanese flounder to obtain effective protective formulations, based on both 692	  
recombinant proteins and DNA vaccine constructs [89, 90]. The most promising 693	  
vaccine concept was the one consisting in a chimeric DNA vaccine coding for the E. 694	  
tarda proteins Eta6 fused in-frame to FliC, the flagellin for E. tarda. Although they 695	  
found that E. tarda FliC induced low protective immunity by itself, it could function as 696	  
a molecular adjuvant and potentiate the specific immune response induced by the E. 697	  
tarda antigen Eta6. Fish immunised with pEta6 and FliC produced specific serum 698	  
antibodies and exhibited enhanced expression of genes that are involved in both innate 699	  
and adaptive immune responses (IL-1ß, IFN, Mx, CD8α, MHC-Iα, MHC-IIα, IgM) 700	  
[89, 90]. Such up regulation following immunisation with flagellin has also been 701	  
described by Hynes et al. [91], where TNF-α, IL-6, IL-8 and IL-1ß were significantly 702	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up regulated compared to non-adjuvanted controls. In this study, however, there was no 703	  
induction of specific antibody response against flagellin or the model antigen Limulus 704	  
polyhemus hemolymph (LPH) in the Atlantic salmon. 705	  
 706	  
4.7. CpG – toll-like receptor 9 agonist 707	  
Bacterial DNA and synthetic oligodeoxynucleotides (ODNs) expressing 708	  
unmethylated CpG motifs trigger an immunostimulatory cascade that culminates in the 709	  
maturation, differentiation and proliferation of multiple immune cells, including B and 710	  
T lymphocytes, NK cells, monocytes, macrophages and dendritic cells. CpG motifs are 711	  
approximately 20 times less common in mammalian than microbial DNA, and therefore 712	  
are recognised as a danger signal by cells that express TLR9. In mammals, it has been 713	  
widely demonstrated that CpG ODNs function as adjuvants when co-administered with 714	  
vaccines, being able to both accelerate and magnify the immune response [92]. In fish, 715	  
although many studies have been carried out on the immunomodulatory effects of CpGs 716	  
[93-96], only few studies have focused on the adjuvant effect of these molecules.  717	  
Chinook salmon (O. tshawytscha) reared in the Pacific Northwest of the United 718	  
States often suffers from infection with Renibacterium salmoninarum, the causative 719	  
agent of bacterial kidney disease (BKD). The conclusion from a study in which whole 720	  
cell vaccines with or without CpG adjuvants were used, was that either the vaccine 721	  
alone or that with CpG provided protection against i.p. challenge with R. salmoninarum 722	  
[93]. However, a combination of a commercial R. salmoninarum vaccine (Renogen) 723	  
with a CpG adjuvant significantly reduced the level of bacterial antigens in the kidney 724	  
of naturally infected fish [93].  725	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In a study in rainbow trout, four groups were i.m. injected with a commercially 726	  
available, non-adjuvanted aqueous vaccine against furunculosis containing inactivated 727	  
cultures of A. salmonicida (Aquavac Furovac 5) alone, or together with CpG ODN 728	  
1982, CpG ODNs 2133 or ODN2143. The fish were challenged with i.p. injection of a 729	  
pathogenic strain of A. salmonicida 7 weeks after injection and the only group that 730	  
showed a significantly lower mortality compared to those injected with Furovac alone 731	  
(mortality of 52%) was the group injected with Furovac and the CpG ODN 2143 in 732	  
which only a 21% of the fish died [94]. 733	  
The protective effect of CpG motifs was also studied by Liu and co-workers in 734	  
turbot and Japanese flounder [95, 96]. Sixteen CpG ODNs were synthesized and 735	  
examined for the ability to inhibit bacterial dissemination in Japanese flounder blood. 736	  
Four ODNs with the strongest inhibitory effects were selected and a plasmid pCN6 was 737	  
constructed containing the sequences of the 4 selected ODNs. Japanese flounder were 738	  
injected i.m. with plasmids pCN6 and pCN3 (control) and PBS. Four weeks post-739	  
vaccination the fish were challenged with A. hydrophila and mortality was monitored 740	  
over a period of 20 days. Accumulated mortalities were 30%, 66.7% and 63.3% in 741	  
pCN6-, pCN3, and PBS-immunised flounder, respectively [96]. Fish were also 742	  
vaccinated as above and challenged with E. tarda 4 weeks after vaccination and the 743	  
mortalities were 53.3, 90%, and 93.3% respectively. Therefore, the pCN6 plasmid 744	  
provided a nonspecific protection against both A. hydrophila and E. tarda infections. 745	  
This nonspecific protective effects have also been observed in fish parasitic infections 746	  
since certain CpGs (e.g. CpG-ODN 1668 and CpG-ODN 2359) have also proved to 747	  
have effects protecting fish against Miamiensis avidus [97]. Following on, a salmonid 748	  
alphavirus (SAV) vaccine containing antigen plus CpG and Poly I:C as adjuvants 749	  
induced a significant production of neutralizing antibodies and conferred some level of 750	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protection – as evaluated by percentage of SAV positive fish compared to controls [98] . 751	  
The authors reported that the adjuvanted vaccines induced prominent IFN type I 752	  
expression – that is crucial in antiviral response. 753	  
To analyse the adjuvant effect of CpGs in turbot, fish were vaccinated with a 754	  
Vibrio harveyi recombinant subunit vaccine, DegQ, in combination with a CpG that had 755	  
been shown to provide anti-bacterial effects in the host species after injection. Fish were 756	  
vaccinated by i.p. injection including all the appropriate controls and twenty-eight days 757	  
after vaccination, the fish were challenged by a virulent strain of V. harvey, and 758	  
accumulated mortalities were recorded [95]. The only vaccine formulation that induced 759	  
a significant protection was DegQ in combination with this pCN5 CpG. The duration of 760	  
the adjuvant effect was found to last at least 50 days. 07/02/2013 761	  
One of the unique features of DNA vaccines is the ability to stimulate both 762	  
cellular and humoral immune responses through the administration of a bacterial 763	  
plasmid coding for a protective antigen [99]. Thus, these DNA vaccines possess 764	  
intrinsic immunostimulatory capacity due to the presence of CpG motifs in the bacterial 765	  
plasmid backbone. Therefore, the inclusion of additional CpG motifs in the vaccine 766	  
plasmid would provide us with an intrinsic adjuvant within the same construct, being an 767	  
easy method to increase the immunogenicity. In this sense, a recent work by Martinez-768	  
Alonso et al. [100] explored the possibility of increasing the immunogenicity of a 769	  
VHSV DNA vaccine though the introduction of several copies (either two or four) of a 770	  
fragment containing multiple CpG sequences of known immunostimulatory effects into 771	  
the DNA vaccine. The addition of these CpG motifs significantly increased the titre of 772	  
neutralising antibodies in serum and increased the levels of transcription of several 773	  
immune genes such as Mx or MHC-I, demonstrating for the first time that additional 774	  
CpG motifs may also be used to increase the immunogenicity of these DNA vaccines.  775	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 776	  
4.8. Cytokines 777	  
In the past years, a great number of cytokine genes have been identified in many 778	  
fish species, however, and despite the fact that the use of cytokines as adjuvants has 779	  
been widely explored in mammals, not many studies have focused on the possible use 780	  
of cytokine genes as vaccine adjuvants in fish. This may be due to the fact that for the 781	  
majority of these molecules, many details concerning their immunological role are still 782	  
lacking, and until we know what immune processes they are regulating, their use would 783	  
be a mere trial and error process. In any case, some attempts to explore their potential 784	  
have been made in some fish species. 785	  
Interferon regulatory factors (IRFs) form a large family of transcription factors. 786	  
IRF-1 has been shown to have a role in cytokine signalling and host defence against 787	  
pathogens. For example, IRF-1 is up-regulated in response to virus infection in fish 788	  
cells, inducing an antiviral state [101]. In a recent study, the potential use of IRF-1 as a 789	  
vaccine adjuvant was investigated in Japanese flounder. The co-injection of IRF-1 with 790	  
a DNA vaccine encoding the major capsid protein (MCP) gene of red sea bream 791	  
iridovirus (RSIV) resulted in elevated serum neutralisation antibodies but was not 792	  
significantly different from that in the fish vaccinated with the DNA vaccine alone 793	  
[102]. Despite the moderate effect in protection, in this study, IRF-1 was responsible for 794	  
the up-regulation of antiviral substances like nitric oxide (NO), interferon ß (IFN ß) and 795	  
interferon inducible genes such as Mx. 796	  
Interleukin 8 (IL-8) is a CXC chemokine produced by many cell types in 797	  
mammals like macrophages, monocytes, epithelial cells, neutrophils and fibroblasts 798	  
upon infection, or stimulated by cytokines like IL-1ß and tumor necrosis factor a (TNF-799	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α). In mammals, chemokines have been widely used as adjuvants in vaccines against 800	  
viral infections, since not only they attract more cells to the site of inflammation, but 801	  
they also regulate the immune functions of the recruited cells. In fish, IL-8 has been 802	  
characterised in rainbow trout among other species, and its chemo attractant properties 803	  
established [103]. In this species, a vaccine plasmid coding for the glycoprotein gene of 804	  
VHSV was co-injected with a plasmid coding for rainbow trout IL-8 to explore its 805	  
potential adjuvant effect [104, 105]. When the plasmid coding of IL-8 (pIL-8+) was 806	  
administered together with the VHSV vaccine, an increase of IL-1ß in the spleen was 807	  
found together with a greater cellular infiltration at the site of inoculation. Furthermore, 808	  
fish injected with pIL-8+ alone showed a significantly higher expression of TNF-α, IL-809	  
11, TGF-ß and IL-18 in the spleen [104]. In a further study, the transcription of different 810	  
inducible CC chemokines were studied in rainbow trout in response to both the VHSV 811	  
DNA vaccine and/or pIL8+, demonstrating that when IL-8 is used as an adjuvant, the 812	  
expression of other chemokines such as CK5A, CK6, CK7 and CK5B is also modulated 813	  
[105]. All these results showed that IL-8 was able to modulate the early immune 814	  
response and could be a potent vaccine adjuvant in fish against viral infections. 815	  
Administration of IL-1ß-derived peptides to rainbow trout by i.p. injection 816	  
induced reduced mortality of fish when exposed to VHSV after 2 days [106]. The 817	  
peptides also induced leukocyte migration into the peritoneal cavity 1-3 days post-818	  
injection, however its possible use as adjuvant was not further explored. The role of IL-819	  
1ß as an adjuvant was investigated in carp after i.p. injection of killed A. hydrophila in 820	  
the absence and presence of recombinant C-terminal peptide of carp IL-1ß. It was found 821	  
that the agglutinating antibody titre was significantly higher in the fish injected with 822	  
killed bacteria plus recombinant IL-1ß peptide compared with killed bacteria alone 3 823	  
weeks after vaccination [107].   824	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 825	  
6. Conclusive remarks and perspectives 826	  
 827	  
The development of effective vaccines should be approached by combining the 828	  
search for protective antigens together with the application of specific, and targeting, 829	  
adjuvants that maximise the immunogenicity with a desired immune response. These 830	  
vaccine-specific adjuvants may be able to trigger specific immunological processes, 831	  
without producing a generalised response with strong side effects. However, an obvious 832	  
consequence for the lack of detailed knowledge on vaccine potency and efficacy using 833	  
novel adjuvants such as the TLR ligands or cytokines - is that the vaccine producers 834	  
may use oil-adjuvants instead for simplicity reason. The oil adjuvants, being able to 835	  
induce very strong and durable immune responses may “overshadow” significant 836	  
protective mechanisms that have been overlooked up till now. Thus, the search for real 837	  
molecular correlates of protection should be pursued with strong efforts. In future 838	  
vaccine research, the immunostimulatory potential of a given substance followed by 839	  
vaccine potency and efficacy studies should be unequivocally established in the context 840	  
of vaccination. Only then, we will be able to convince the pharmaceutical industry to 841	  
move from traditional adjuvants to more sophisticated adjuvants that specifically trigger 842	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Table 1. Adjuvants, central components, receptors/process and principal immunological 1179	  
responses elicited by licensed and experimental adjuvants mainly for human medicine. 1180	  
Adapted from Coffman et al. [57]. 1181	  
 1182	  
 1183	  
Abbreviations and descriptions: MF59 (Novartis proprietary adjuvant MF59 containing 1184	  
squalene, polyoxyethylene sorbitan monooleate and sorbitan trioleate), AS03 1185	  
(GlaxoSmithKline) contains squalene, DL-a-tocopherol, polysorbate), AS04 (Aluminum 1186	  
hydroxide and monophoshoryl lipid A (MPL), ISCOMs (immune stimulating complex; 1187	  
nanostructure of cholesterol, phospholipids and Quil-A saponis), IFA (incomplete Freund´s 1188	  
adjuvants). Ab: antibodies. 1189	  
 1190	  
 1191	  




PPR/Process Principal immune response elicited 
Alum 
MF59 and AS03 
 
Aluminum salts 




Ab, Th2 (+Th1 in humans) 
Ab, Th1 and Th2 
AS04 MPL + Alum TLR4 and 
NLRP3(?) 
Ab and Th1 
    
Adjuvants in experimental use or in late stage clinical development 
Poly I:C Synthetic dsRNA  Ab, Th1, CTL 
MPL, and in diff. 
formulations 
  Ab, Th1 
Flagellin, flagellin-










TLR7, TLR8 and 
both 
Ab, Th1, CTL (when conjugated) 








with optimized CpG 
motifs 
TLR9 Ab, Th1, CTL (when conjugated) 




Mineral or paraffin 
oil + surfactant 
Not defined Ab, TH1 + Th2 
    
CFA IFA + 
peptidoglycan, 
trehalose dimycolate 
NLR, TLR? Ab, Th1, Th17 
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Table 2. Adjuvants currently used in fish vaccines commercialised by the main fish 1193	  
vaccine manufacturers.  1194	  
Company Vaccine name Pathogen Adjuvant Immunization 
route 
PHARMAQ Alpha Ject and Alpha 




Mineral oil i.p. 
Alpha Dip  No adjuvant Immersion 
MSD Animal 
Health 
AquaVac  A. salmonicida, Y. 
ruckeri, Vibrio  
No adjuvant i.p., immersion 
AquaVac FNMPlus A. salmonicida Montanide 
ISA711 
i.p. 






AquaVac ERM Oral Y. ruckeri, Vibrio No adjuvant oral 







Ermogen Y. ruckeri No adjuvant Immersion 
Apex®-IHN IHNV No adjuvant i.m. 
 1195	  
 1196	  
 1197	  
